Table 4.
Selected studies for therapy of uveal melanoma.
| Study | Study Type | N | Arms (n) | ORR (%) | DCR (%) | PFS (mo) | OS (mo) |
|---|---|---|---|---|---|---|---|
| Luke et al. 2013 [172] | Multicenter, retrospective | 39 | Ipilimumab | 2.6 | 46 | - | 9.6 |
| Piulats et al. 2014 [173] | Phase 2 | 32 | Ipilimumab | 6.45 | 50 | NS | NS |
| Carvajal et al. 2014 [169] | Phase 2 | 101 | Selumetinib (50) Chemotherapy (51) |
14 0 |
NS | 3.7 1.6 |
11.8 9.1 |
| Zimmer et al. 2015 [174] | Phase 2 | 53 | Ipilimumab | 0 | 47 | 2.8 | 6.8 |
| Joshua et al. 2015 [175] | Phase 2 | 11 | Tremelimumab | 0 | - | 2.9 | 12.8 |
| Shoushtari et al. 2016 [171] | Phase 2 | 39 | Trametinib (18) Trametinib + GSK2141795 a (21) |
5.5 4.8 |
NS | 3.6 3.6 |
NS |
| Tsai et al. 2016 [176] | Multicenter, retrospective | 58 | Pembrolizumab (40) Nivolumab (16) Atezolizumab (2) |
3 | 10 | 2.7 | 9.5 |
| Piulats et al. 2017 [177] | Phase 2 | 19 | Nivolumab + Ipilimumab | 15.8 | 63.2 | 4.99 | NR |
| Scheulen et al. 2017 [178] | Phase 2 | 118 | Sorafenib | 1.7 | 66.1 | 5.5 | 14.8 |
| Patel et al. 2017 [179] | Phase 2 | 31 | Glembatumumab Vedotin b | 6 | 61 | 3.2 | 11.8 |
| Mignard et al. 2018 [138] | Multicenter, Retrospective | 100 | Ipilimumab (63) Nivolumab or Pembrolizumab (37) |
0 | 32 | - | 13.38 |
| Carvajal et al. 2018 [170] | Phase 3 | 129 | Selumetinib + Dacarbazine (97) Placebo + Dacarbazine (32) |
3 0 |
NS | 2.8 1.8 |
NS |
| Sato et al. 2018 [180] | Phase 1/2 | 19 | Tebentafusp c | 10.5 d | - | - | NR |
Abbreviations: ORR, overall response rate; DCR, disease control rate; PFS, progression-free survival; OS, overall survival; NS, not specified; NR, not reached. a AKT inhibitor; b monoclonal antibody-drug conjugate against NMB; c bispecific protein IMCgp100; d minor responses in 4 patients.